40626-29-7

Basic information

• Product Name: D-(+)-Norephedrine hydrochloride
• Synonyms: hydrochloride,(+)-norephedrin;(1S,2R)-(+)-NOREPHEDRINE HYDROCHLORIDE;(1S,2R)-2-AMINO-1-PHENYL-1-PROPANOL HYDROCHLORIDE;D-(+)-NOREPHEDRINE HYDROCHLORIDE;(+)-PHENYLPROPANOLAMINE HYDROCHLORIDE;(1S,2R)-(+)-phenylpropanolamine*hydrochloride;d-NOREPHEDRINE HCl;(IS,2R)-d-Norephedrine HCI
• CAS NO: 40626-29-7
• Molecular Formula: C₉H₁₃NO*ClH
• Molecular Weight: 187.67
• EINECS: 255-008-9
• Mol File: 40626-29-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 174-176 °C(lit.)
• Boiling Point: 288.1 °C at 760 mmHg
• Flash Point: 128.1 °C
• Appearance: WHITE POWDER OR CRYSTALLINE POWDER AND/OR CHUNKS
• Density: g/cm³
• Vapor Pressure: 0.0011mmHg at 25°C
• CAS DataBase Reference: D-(+)-Norephedrine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: D-(+)-Norephedrine hydrochloride(40626-29-7)
• EPA Substance Registry System: D-(+)-Norephedrine hydrochloride(40626-29-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 26
• WGK Germany: 3
• RTECS: RC3325000
• Hazardous Substances Data: 40626-29-7(Hazardous Substances Data)

Usage

Uses

(1S,2R)-(+)-Norephedrine Hydrochloride is used in preparation of pyrrolopyridines as ERK inhibitors useful in treatment of diseases.

InChI:InChI=1/C9H13NO.ClH/c1-7(10)9(11)8-5-3-2-4-6-8;/h2-7,9,11H,10H2,1H3;1H/t7-,9-;/m1./s1

Upstream product

• 154-41-6 erythro-1-phenyl-1-hydroxy-2-propylammonium chloride 
• 4380-71-6 erythro-2-benzoylamino-1-phenylpropan-1-ol 
• 38222-77-4 trans-2,5-diphenyl-4-methyl-1,3-oxazoline 
• 38222-78-5 threo-1-benzoyloxy-1-phenyl-2-propylammonium chloride 
• 1369998-47-9 (1R,2R)-1-phenyl-2-(1-piperidinyl)-1-chloropropane hydrochloride 
• 154-41-6 norephedrine hydrochloride 
• 135028-68-1 <2S-(2a(R*),3aα,4β,7β,7aα)>-α-<(octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl)oxy>benzolacetonitril 
• 532-28-5 (RS)-mandelonitrile 
• 133735-62-3 <2S-(2a(αS*,βR*),3aα,4β,7β,7aα)>-α-methyl-β-<(octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl)oxy>benzolethanamin 
• 910471-77-1 2-(tert-butyldiphenylsilyloxy)-2-phenylacetonitrile 
• 100-52-7 benzaldehyde 
• 42407-55-6 (1RS,2RS)-2-dibenzylamino-1-phenyl-propan-1-ol; hydrochloride 
• 26251-08-1 2-nitro-1-phenylpropan-1-ol 

Downstream Products

• 81581-16-0 (2R,4R,5S)-2-dimethylamino-4-methyl-5-phenyl-1,3,2-oxazaphospholidine-2-thione 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 492-41-1 (1R,2S)-norephedrine 
• 3198-15-0 (1R,2S)-(-)-norephedrine hydrochloride 
• 1592-59-2 threo-1-chloro-1-phenyl-2-propylammonium chloride 
• 37577-07-4 Norpseudoephedrine 
• 492-39-7 (1S,2S)-2-amino-1-phenylpropanol 
• 39861-30-8 2-chloro-1-methyl-2-phenyl-ethylamine; hydrochloride 
• 1592-59-2 erythro-1-chloro-1-phenyl-2-propylammonium chloride 
• 38222-78-5 threo-1-benzoyloxy-1-phenyl-2-propylammonium chloride 
• 1630-31-5 trans-5-phenyl-4-methyl-1,3-thiazolidine-2-thione 
• 78393-88-1 erythro-1-chloro-1-phenyl-2-isothiocyanatopropane 
• 78393-88-1 threo-1-chloro-1-phenyl-2-isothiocyanatopropane 
• 78373-96-3 trans-5-phenyl-2-methoxy-4-methyl-1,3-thiazoline 

Relevant articles and documents

A NOVEL METHOD FOR SYNTHESIS OF OPTICALLY PURE BETA-AMINO ALCOHOLS

A method for the preparation of β-amino alcohol of formula (III) in which R1 is Ph, (substituted) Ph, R2 is C1-8 alkyl or C4-6 cyclo alkyl, R3 = R4R5CHNH2 where, R4 = H, C1-8 alkyl, C4-6 cyclo alkyl, or - COOR6 (R6=C1-C8 alkyl); R5 = (subst) aryl], the method including subjecting an α-hydroxy ketone of formula (I) in which R1 and R2 are as defined above is reacted with a chiral amine of formula R3NH2 where R3 = R4R5CH- where, R4 = H, C1-8 alkyl, C4-6 cycloalkyl, or - COOR6 (R6=C1-8 alkyl), R5 = (subst) aryl] to produce a compound of formula (II) in which R1, R2 and R3 are as defined above, followed by reduction to form the compound of formula (III).

Remarkable enantioselective α-amination in 1-phenyl-2-(N-alkylamino)- 1-propanol

(1R,2R)-1-Phenyl-1-alkyl/arylamino-2-(N-alkylamino)propane hydrochloride salts have been synthesized with high degree of enantiomeric purity from (1S,2R)-(+)-1-phenyl-2-(N-alkylamino)-1-propanol through the corresponding chloro derivatives. This reaction sequence involves three inversions with overall inversion of configuration at C-1. Copyright

Controlled release pharmaceutical preparation

A controlled release pharmaceutical preparation comprising a core containing a medicinal compound and a coating layer containing a water-repellent salt and a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group. Said preparation releases a medicinal compound in a sigmoid type dissolution pattern irrespective of the PH of a dissolution medium.